| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 227 |
| 1 | PREDNISONE | 44 |
| 2 | CYCLOPHOSPHAMIDE | 38 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 38 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 38 |
| 5 | DOXORUBICIN | 31 |
| 6 | PREDNISOLONE | 27 |
| 7 | PREDNISOLONE ORAL | 27 |
| 8 | PREDNISOLONE ORAL SOLUTION | 27 |
| 9 | BENDAMUSTINE HCL | 20 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BENDAMUSTINE HCL | 20 | 0.0013 |
| 1 | RITUXIMAB | 227 | 0.0011 |
| 2 | BRODALUMAB | 1 | 0.0005 |
| 3 | REMDESIVIR | 6 | 0.0005 |
| 4 | DOXORUBICIN | 31 | 0.0003 |
| 5 | AMISULPRIDE | 2 | 0.0003 |
| 6 | OBINUTUZUMAB | 5 | 0.0003 |
| 7 | OCRELIZUMAB | 17 | 0.0003 |
| 8 | CHLORAMBUCIL | 1 | 0.0003 |
| 9 | BAYER ASPIRIN EXTRA STRENGTH | 1 | 0.0003 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 241 | 0.0007 |
| 1 | Interleukin-17 Receptor A Antagonist [EPC] | 1 | 0.0005 |
| 2 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 6 | 0.0005 |
| 3 | Dopamine-2 Receptor Antagonist [EPC] | 2 | 0.0003 |
| 4 | Alkylating Drug [EPC] | 39 | 0.0002 |
| 5 | Hedgehog Pathway Inhibitor [EPC] | 1 | 0.0001 |
| 6 | Antimetabolite Immunosuppressant [EPC] | 2 | 0.0001 |
| 7 | Interleukin-2 Receptor Blocking Antibody [EPC] | 1 | 0.0001 |
| 8 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 1 | 0.0001 |
| 9 | Interleukin-1 Receptor Antagonist [EPC] | 1 | 0.0001 |